Home Publications


Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity
Loo D, Alderson R, Chen F, Huang L, Zhang W, Gorlatov S, Burke S, Ciccarone V, Li H, Yang Y, Son T, Chen Y, Easton A, Li J, Rillema J, Licea M, Fieger C, Liang T, Mather J, Koenig S, Stewart S, Johnson S, Bonvini E, Moore P. Clinical Cancer Research 2012; doi:10.1158/1078-0432.CCR-12-0715

MGD006 (CD123xCD3 DART)

A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates
Chichili G, Huang L, Li H, Burke S, He L, Tang Q, Jin L, Gorlatov S, Ciccarone V, Chen F, Koenig S, Shannon M, Alderson R, Moore P, Johnson S, Bonvini E. Sci Transl Med 27 May 2015; Vol. 7, Issue 289, 289ra82.

Cancer Stem Cells Platform

Culture of pluripotent neural epithelial progenitor cells from E9 rat embryo
Li R, Mather JP. Methods in Cell Biology 2008;86:227-40.

Primary and multipassage culture of human fetal kidney epithelial progenitor cells
Loo D, Beltejar C, Hooley J, Xu X. Methods in Cell Biology 2008;86:241-55.

Antibody-based identification of cell surface antigens: targets for cancer therapy
Loo DT, Mather JP. Current Opinion in Pharmacology 2008 October;8(5):627-31.

Stem cell culture. Preface.
Mather JP. Methods in Cell Biology 2008;86:xv-xvii.

Isolation and establishment of human tumor stem cells
Roberts PE. Methods in Cell Biology 2008;86:325-42.

DART™ (Dual-Affinity Re-Targeting) Platform

Application of dual-affinity re-targeting (DART) molecules to achieve optimal redirected t-cell killing of b-cell lymphoma
Paul A. Moore, Wenjun Zhang, G. Jonah Rainey, Steve Burke, Hua Li, Ling Huang, Sergey Gorlatov, Maria Concetta Veri, Sudeppta Aggarwal, Yinhua Yang, Kaplana Shah, Linda Jin, Sunan Zhang, Leilei He, Tengfei Zhang, Valentina Ciccarone, Scott Koenig, Ezio Bonvini and Syd Johnson; Blood, 2011; 117(17):4542-4551.

Therapeutic control of b-cell activation via recruitment of Fcgamma receptor IIB (CD32B) inhibitory function with a novel bispecific antibody scaffold
Veri MC, Burke S, Huang L, Li H, Gorlatov S, Tuaillon N, et al. Arthritis Rheum, 2010 Mar 30;62(7):1933-43.

Effector cell recruitment with novel fv-based dual-affinity retargeting protein leads to potent tumor cytolysis and in vivo b-cell depletion
Johnson S, Burke S, Huang L, Gorlatov S, Li H, Wang W, et al. J Mol Biol, 2010 Apr 9;399(3):436-49.

Fc Optimization Platform

Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells In vitro and controls tumor expansion in vivo via low-affinity activating fc receptors
Jeffrey B. Stavenhagen, Sergey Gorlatov, Nadine Tuaillon, Christopher T. Rankin, Hua Li, Stephen Burke, Ling Huang, Syd Johnson, Ezio Bonvini and Scott Koenig. Cancer Research 2007 Sep 15; 67(18):8882-90.

Enhancing the potency of therapeutic monoclonal antibodies via Fc optimization
Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, Huang L, Johnson S, Koenig S, Bonvini E. Advances in Enzyme Regulation 2007 December 3.

Teplizumab (Anti-CD3)

The Compelling Case for Anti-CD3 in Type 1 Diabetes
Jay S. Sklyer

Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline identify a subgroup of responders
Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA; the AbATE Study Team. Diabetes 2013 Jul 8. [Epub ahead of print]

Teplizumab preserves C-peptide in recent-onset type 1 diabetes: 2-year results from the randomized, placebo-controlled Protégé trial
Hagopian W, Ferry RJ Jr, Sherry N, Carlin D, Bonvini E, Johnson S, Stein KE, Koenig S, Daifotis AG, Herold KC, Ludvigsson J; for the Protégé Trial Investigators. Diabetes 2013 Jun 25. [Epub ahead of print]

Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial
Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, Sherr J, Rosenthal SM, Adi S, Jalaludin MY, Michels AW, Dziura J, Bluestone JA. Diabetologia 2013 Feb;56(2):391-400.

Anti-CD3 clinical trials in type 1 diabetes mellitus
Daifotis A, Koenig S, Chatenoud L, Herold KC. Clinical Immun 2013 May 11.doi:pii: S1521-6616(13)00120-4. 10.1016/j.clim.2013.05.001. [Epub ahead of print]

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial
Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr, Bode B, Aronoff S, Holland C, Carlin D, King KL, Wilder RL, Pillemer S, Bonvini E, Johnson S, Stein KE, Koenig S, Herold KC, Daifotis AG; Protégé Trial Investigators. Lancet 2011 Aug 6;378(9790):487-97.

Immunomodulatory therapy to preserve pancreatic ?-cell function in type 1 diabetes
Waldron-Lynch F, Herold KC. Nat Rev Drug Discov 2011 Jun;10(6):439-52.

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA. N Engl J Med 2002 May 30;346(22):1692-8.

TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs
Bisikirska B, Colgan J, Luban J, Bluestone JA, Herold KC. J Clin Invest 2005 Oct;115(10):2904-13.

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes
Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA. Diabetes 2005 Jun;54(6):1763-9.

CD3-specific antibodies: a portal to the treatment of autoimmunity
Chatenoud L, Bluestone JA. Nat Rev Immunol 2007 Aug;7(8):622-32.

MGAWN1 (West Nile Virus)

Development of a humanized monoclonal antibody with therapeutic potential against West Nile Virus
Oliphant, T., Engle, M., Nybakken, G.E., Doane, C., Johnson, S., Huang, L., Gorlatov, S., Mehlhop, E., Marri, A., Chung, K.M., Ebel, G.D., Kramer, L.D., Fremont, D.H., and Diamond, M.S. Nature Medicine. 2005 May; 11(5):522-30.

Structural basis of West Nile virus neutralization by a therapeutic antibody
Nybakken, G.E., Oliphant, T., Johnson, S., Burke, S., Diamond, M.S., Fremont, D.H. Nature 2005 Sep 29;437(7059):764-9.

Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters
Morrey JD, Siddharthan V, Olsen AL, Roper GY, Wang H, Baldwin TJ, Koenig S, Johnson S, Nordstrom JL, Diamond MS. Journal of Infectious Diseases 2006 November 1;194(9):1300-8.

Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model
Morrey JD, Siddharthan V, Olsen AL, Wang H, Julander JG, Hall JO, Li H, Nordstrom JL, Koenig S, Johnson S, Diamond MS. Antimicrobial Agents Chemotherapy Journal 2007 July;51(7):2396-402.

Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus
Pletnev A, St. Claire M, Elkins R, Speicher J, Murphy B, Chanock R. Virology 2003 September;314(1):190-5.

MGARG2 (Anti-RAAG12)

Phase 1 Experience with an Anti-Glycotope Monoclonal Antibody, RAV12, in Recurrent Adenocarcinoma
Burris H, Rosen L, Rocha-Lima C, Marshall J, Jones S, Cohen R, Kunkel L, Loo D, Baughman J, Stewart S and Lewis N. Clin Cancer Res 2010 March 16;1673.

RAV12 accelerates the desensitization of Akt/PKB pathway of insulin-like growth factor I receptor signaling in COLO205
Li JC, Li R. Cancer Research 2007 September 15;67(18):8856-64.

The glycotope-specific RAV12 monoclonal antibody induces oncosis in vitro and has antitumor activity against gastrointestinal adenocarcinoma tumor xenografts in vivo
Loo D, Pryer N, Young P, Liang T, Coberly S, King KL, Kang K, Roberts P, Tsao M, Xu X, Potts B, Mather JP. Molecular Cancer Therapeutics 2007 March;6(3):856-65.


Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fc-gamma receptor binding properties
Nordstrom J, Gorlatov S, Zhang W, Yang Y, Huang L, Burke S. Li H, Ciccarone V, Zhang T, Stavenhagen J, Koenig S, Stewart S, Moore P, Johnson S, Bonvini E. Breast Cancer Research, 2011 November 30;13:R123.


Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization
Veri, M.C., Gorlatov, S., Li, H., Burke, S., Johnson, S., Stavenhagen, J., Stein, K. E., Bonvini, E., Koenig, S. Immunology. 2007 Jul;121(3) 392-404.

CD32B, the human inhibitory Fc- receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma
Rankin, C.T., Veri, M.C., Gorlatov, S., Tuaillon, N., Burke, S., Huang, L., Inzunza, H.D., Li, H., Thomas, S., Johnson, S., Stavenhagen, J., Koenig, S., and Bonvini, E. Blood 2006 Oct 1;108(7):2384-91.

Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions
Boruchov, A.M., Heller, G., Veri, M.C., Bonvini, E., Ravetch, J.V., and Young, J.W. J. Clin. Invest. 2005 Oct; 115(10):2914-23.

Selective blockade of inhibitory Fc receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells
Dhodapkar, K.M., Kaufman, J.L., Ehlers, M., Banerjee, D.K., Bonvini, E., Koenig, S., Steinman, R.M., Ravetch, J.V., and Dhodapkar, J.V. Proc. Natl. Acad. Sci. USA 2005 Feb 22;102(8):2910-5.

Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE
Mackay M, Stanevsky A, Wang T, Aranow C, Li M, Koenig S, Ravetch JV, Diamond B. J. Exp. Med. 2006; September 4;203(9):2157-64.

The functional variant of the inhibitory Fcgamma receptor IIb (CD32B) is associated with the rate of radiologic joint damage and dendritic cell function in rheumatoid arthritis
Radstake TR, Franke B, Wenink MH, Nabbe KC, Coenen MJ, Welsing P, Bonvini E, Koenig S, van den Berg WB, Barrera P, van Riel PL. Arthritis & Rheumatism 2006 December;54(12):3828-37.


A rapid method for determining dynamic binding capacity of resins for the purification of proteins
Do T, Ho F, Heidecker B, Witte K, Chang L, Lerner L. Protein Expr. Purif. 2008 August;60(2):147-50.

A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs
Gopi Shankar, Charles Pendley & Kathryn E. Stein. Nature Biotechnology 2007;25,555-561.

Association between polymorphism in IgG receptor IIIa coding gene and biological response to infliximab in Crohn's disease
Louis E, El Ghoul Z, Vermeire S, Dall'Ozzo S, Rutgeerts P, Paintaud G, Belaiche J, De Vos M, Van Gossum A, Colombel JF, Watier H. Aliment Pharmacol Ther. 2004 Mar 1;19(5):511-9.

Please note – you will leave a website owned by MacroGenics, Inc.

MacroGenics is not responsible for any content on the third party website.

Ok Close